Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

BACKGROUND AND OBJECTIVE: Risankizumab is an anti-interleukin (IL)-23 monoclonal antibody being developed for treatment of moderate to severe plaque psoriasis. This study provided a comprehensive analysis of risankizumab pharmacokinetics in healthy subjects and patients with plaque psoriasis using d...

Descripción completa

Detalles Bibliográficos
Autores principales: Suleiman, Ahmed A., Minocha, Mukul, Khatri, Amit, Pang, Yinuo, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769095/
https://www.ncbi.nlm.nih.gov/pubmed/31054118
http://dx.doi.org/10.1007/s40262-019-00759-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769095/
https://www.ncbi.nlm.nih.gov/pubmed/31054118
http://dx.doi.org/10.1007/s40262-019-00759-z

Ejemplares similares